As an orally available inhibitor of endothelin-1, which has been implicated in the pathogenesis of vascular disease in systemic sclerosis (SSc), bosentan is widely used as first-line therapy for ...

Bosentan is a dual endothelin-1-receptor antagonist that effectively treats idiopathic PAH and PAH related to connective tissue disease. Following preliminary trials of bosentan for the treatment ...

This leaflet answers some common questions about BOSENTAN VIATRIS. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

News, May 13, 2009 FDA Safety Changes: Visicol, OsmoPrep, DiaBeta, Raptiva The FDA has approved safety labeling revisions for sodium phosphate monobasic monohydrate and sodium phosphate dibasic ...

Natco Pharma Ltd has received final approval from the USFDA to market Bosentan 32mg tablets. This drug, Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension (PAH).